MyFinsight
Home
Blog
About
Contact
Download
Download image
Oral Solid
$171,100K
Transdermal
$73,963K
(71.76%↑ Y/Y)
Injectable
$49,938K
(43.55%↑ Y/Y)
Other Dosage Forms
$46,612K
Ephinephrine Auto Injector
$41,912K
Biosimilar
$22,301K
(-21.86%↓ Y/Y)
Oral Liquid
$12,092K
Subtotal Dosage Forms
$417,918K
International
$5,319K
(331.04%↑ Y/Y)
Distribution Service
$89,149K
Government Label
$59,949K
Institutional
$9,819K
(-10.81%↓ Y/Y)
Product And Service
Other
$7,100K
Central Nervous System
$83,383K
Hormonal Allergy
$35,932K
Other Therapeutic
Classes
$13,950K
Affordable Medicines
Segment
$423,237K
Av KARESegment
$166,017K
(-3.71%↓ Y/Y)
Specialty
Segment-Subtotal Therapeutic...
$133,265K
Net revenue
$722,519K
(3.90%↑ Y/Y)
Gross profit
$320,113K
(25.10%↑ Y/Y)
Other operating
income
$6,941K
(35.51%↑ Y/Y)
Cost of goods sold
$402,406K
(-8.45%↓ Y/Y)
Operating income (loss)
$141,772K
(41.28%↑ Y/Y)
Selling, general and
administrative
$138,860K
(17.39%↑ Y/Y)
Research and development
$38,383K
(-4.14%↓ Y/Y)
Acquisition costs
$5,153K
Intellectual property legal
development expenses
$1,542K
(-12.73%↓ Y/Y)
Charges related to legal
matters, net
-$694K
Restructuring and other
charges
$650K
(13.84%↑ Y/Y)
Income before income
taxes
$80,176K
(113.88%↑ Y/Y)
Total other expense,
net
-$61,596K
(2.01%↑ Y/Y)
Decrease (increase) in
tax receivable...
$2,333K
(121.83%↑ Y/Y)
Other income, net
$742K
(43.24%↑ Y/Y)
Corporate Non Segment
$46,171K
(21.82%↑ Y/Y)
Affordable Medicines
Segment-Operating Segments
$41,318K
(22.55%↑ Y/Y)
Amneal Specialty
Pharma...
$34,691K
(11.99%↑ Y/Y)
Av
KARESegment-Operating Segments
$16,680K
(6.28%↑ Y/Y)
Net income
$78,000K
(216.84%↑ Y/Y)
Provision for income taxes
$2,176K
(-83.09%↓ Y/Y)
Interest expense, net
-$53,361K
(6.28%↑ Y/Y)
Foreign exchange (gain)
loss, net
-$7,800K
(-283.66%↓ Y/Y)
Gain on refinancing
-$3,510K
Back
Back
Income Statement
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)
source: myfinsight.com